Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease in the elderly, and no cure or disease-modifying therapies exist. Several lines of evidence suggest that mitochondrial dysfunction and oxidative stress have a central role in the dopaminergic neurodegeneration of PD. In this context, mitochondria-targeted therapies that improve mitochondrial function may have great promise in the prevention and treatment of PD. In this review, we discuss the recent developments in mitochondria-targeted antioxidants and their potential beneficial effects as a therapy for ameliorating mitochondrial dysfunction in PD.
Full text
Read the full text of Mitochondria-Targeted Antioxidants for Treatment of Parkinson’s Disease: Preclinical and Clinical Outcomes, originally published in Biochim Biophys Acta. 2014 Aug; 1842(8): 1282–1294., 2013 Sep 20. doi: 10.1016/j.bbadis.2013.09.007, on the National Library of Medicine PubMed Central website.